Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

The influence of obesity and consequent insulin resistance on coronary risk factors in medically treated patients with coronary disease

International Journal of Obesity volume 32, pages 967–974 (2008)Cite this article

Abstract

Objective:

Obesity promotes the development and progression of coronary heart disease (CHD), in part, through its association with hyperlipidemia, hypertension, clotting abnormalities and insulin resistance. We assessed whether these relationships persist in patients with established CHD treated with evidence-based preventive pharmacologic therapies.

Design and subjects:

We performed a cross-sectional study of 74 adults with CHD and a body mass index (BMI) of >27 kg m–2 (mean 32±4). The mean age of subjects was 64±9 years (range 44–84 years).

Measurements:

Obesity measures included weight, BMI, waist, fat mass, intra-abdominal fat and subcutaneous fat. Risk factor measures included insulin sensitivity, fasting insulin level, lipid profiles, blood pressure, C-reactive protein (hs-CRP), plasminogen activator inhibitor (PAI-1) and platelet reactivity. Medication use included aspirin (99%), statin (84%), β-blocker (71%), ACE inhibitor or blocker (37%) and clopidogrel (28%).

Results:

There was no direct relationship between obesity parameters and risk factor measures of lipid concentrations, blood pressure, clotting abnormalities or platelet reactivity except for a modest relationship between visceral fat and hs-CRP (r=0.30, P=0.02). However, increased BMI, waist circumference, fat mass, total abdominal fat and abdominal subcutaneous fat all correlated with insulin sensitivity (r-values −0.30 to −0.45, P-values 0.01 to <0.001) and insulin concentrations. Insulin sensitivity, in turn, was the best predictor of PAI-1, triglycerides, high-density lipoprotein (HDL) levels, cholesterol/HDL levels (all P<0.01) and platelet reactivity (R=0.34, P=0.02).

Conclusions:

Use of preventive pharmacologic therapies obviated the expected relationship between adiposity and CHD risk factors. However, a residual effect of insulin resistance is left untreated. Total adiposity and central adiposity were strong predictors of insulin sensitivity, which in turn predicted cardiac risk factors such as lipid concentrations, PAI-1 and platelet reactivity. Thus, while evidence-based pharmacologic treatments may diminish the statistical relationship between obesity and many cardiac risk factors, adiposity negatively impacts CHD risk by reducing tissue insulin sensitivity.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

Similar content being viewed by others

References

  1. Wilson PW, D'Agostino RB, Sullivan L, Parise H, Kannel WB . Overweight and obesity as determinants of cardiovascular risk: the Framingham experience. Arch Intern Med 2002; 162: 1867–1872.

    Article  Google Scholar 

  2. Yusuf S, Hawken S, Ounpuu S, Bautista L, Franzosi MG, Cammerford P et al., INTERHEART Study Investigators. Obesity and the risk of myocardial infarction in 27 000 participants from 52 countries: a case–control study. Lancet 2005; 366: 1640–1649.

    Article  Google Scholar 

  3. Ruige JB, Assendelft WJ, Dekker JM, Kostense PJ, Heine RJ, Bouter LM . Insulin and risk of cardiovascular disease: a meta-analysis. Circulation 1998; 97: 996–1001.

    Article  CAS  Google Scholar 

  4. Despres JP, Lamarche B, Mauriege P, Cantin B, Dagenais GR, Moorjani S et al. Hyperinsulinemia as an independent risk factor for ischemic heart disease. N Engl J Med 1996; 334: 952–957.

    Article  CAS  Google Scholar 

  5. Rana JS, Mukamal KJ, Morgan JP, Muller JE, Mittleman MA . Obesity and the risk of death after acute myocardial infarction. Am Heart J 2004; 147: 841–846.

    Article  Google Scholar 

  6. Wolk R, Berger P, Lennon RJ, Brikalis ES, Somers VK . Body mass index: a risk factor for unstable angina and myocardial infarction in patients with angiographically confirmed coronary artery disease. Circulation 2003; 108: 2206–2211.

    Article  Google Scholar 

  7. Rea TD, Heckbert SR, Kaplan RC, Pstay BM, Smith NL, Lemaitre RN et al. Body mass index and the risk of recurrent coronary events following acute myocardial infarction. Am J Cardiol 2001; 88: 467–472.

    Article  CAS  Google Scholar 

  8. Rana JS, Nieuwdorp M, Jukema JW, Kastelein JJ . Cardiovascular metabolic syndrome—an interplay of obesity, inflammation, diabetes and coronary heart disease. Diabetes Obes Metab 2007; 9: 8–32.

    Article  Google Scholar 

  9. Lee YH, Pratley RE . Abdominal obesity and cardiovascular disease risk: the emerging role of the adipocyte. J Cardiopulm Rehabil Prev 2007; 27: 2–10.

    Article  Google Scholar 

  10. Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R et al. Pravastatin or atorvastatin evaluation and infection therapy-thrombolysis in myocardial infarction 22 investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004; 350: 1495–1504.

    Article  CAS  Google Scholar 

  11. Boden WE, O'Rourke RA, Teo KK, Hartigen PM, Maron DJ, Kostuk WJ et al., COURAGE Trial Research Group. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med 2007; 356: 1503–1516.

    Article  CAS  Google Scholar 

  12. Evans DJ, Murray R, Kissebah AH . Relationship between skeletal muscle insulin resistance, insulin-mediated glucose disposal, and insulin binding. Effects of obesity and body fat topography. J Clin Invest 1984; 74: 1515–1525.

    Article  CAS  Google Scholar 

  13. Fujioka S, Matsuzawa Y, Tokunaga K, Tarui S . Contribution of intra-abdominal fat accumulation to the impairment of glucose and lipid metabolism in human obesity. Metabolism 1987; 36: 54–59.

    Article  CAS  Google Scholar 

  14. Reaven GM . Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988; 37: 1595–1607.

    Article  CAS  Google Scholar 

  15. Ferrannini E, Balkau B, Coppack SW, Dekker JM, Mari A, Nolan J et al. Insulin resistance, insulin response, and obesity as indicators of metabolic risk. J Clin Endocrinol Metab 2007; 92: 2885–2892.

    Article  CAS  Google Scholar 

  16. Ades PA, Savage PD, Brawner CA, Lyon CE, Ehrman JK, Bunn JY et al. Aerobic capacity in patients entering cardiac rehabilitation. Circulation 2006; 113: 2706–2712.

    Article  Google Scholar 

  17. Bader DS, Maguire TE, Spahn CM, O'Malley CJ, Balady GJ . Clinical profile and outcomes of obese patients in cardiac rehabilitation stratified according to National Heart, Lung, and Blood Institute criteria. J Cardiopulm Rehabil 2001; 21: 210–217.

    Article  CAS  Google Scholar 

  18. Tchernof A, Nolan A, Sites CK, Ades PA, Poehlman ET . Weight loss reduces C-reactive protein levels in obese postmenopausal women. Circulation 2002; 105: 564–569.

    Article  Google Scholar 

  19. Schneider DJ . Abnormalities of coagulation, platelet function, and fibrinolysis associated with syndromes of insulin resistance. Coron Artery Dis 2005; 16: 473–476.

    Article  Google Scholar 

  20. Savage PD, Banzer JA, Balady GJ, Ades PA . Prevalence of metabolic syndrome in cardiac rehabilitation/secondary prevention programs. Am Heart J 2005; 149: 627–631.

    Article  Google Scholar 

  21. Toth MJ, Sites CK, Cefalu WT, Matthews DE, Poehlman ET . Determinants of insulin-stimulated glucose disposal in middle-aged, premenopausal women. Am J Physiol 2001; 281: E113–E121.

    CAS  Google Scholar 

  22. DeFronzo R, Tobin J, Andres R . Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 1979; 237: E214–E233.

    CAS  Google Scholar 

  23. Fong Y, Matthews DE, He W, Marano MA, Moldawer LL, Lowry SF . Whole body and splanchnic leucine, phenylalanine, and glucose kinetics during endotoxemia in humans. Am J Physiol 1994; 266: R419–R425.

    CAS  PubMed  Google Scholar 

  24. Bier DM, Arnold KJ, Sherman WR, Holland WH, Holmes WF, Kipnis DM . In vivo measurement of glucose and alanine metabolism with stable isotopic tracers. Diabetes 1997; 26: 1005–1015.

    Article  Google Scholar 

  25. Allain CC, Poon LS, Chang CS, Richmond W, Fu PC . Enzymatic determination of total serum cholesterol. Clin Chem 1974; 20: 470–478.

    CAS  PubMed  Google Scholar 

  26. Friedewald WT, Levy RI, Fredrickson DS . Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without the use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499–507.

    CAS  Google Scholar 

  27. Chmielewska J, Wiman B . Determination of plasminogen activator and its ‘fast’ inhibitor in plasma. Clin Chem 1986; 32: 482–485.

    CAS  PubMed  Google Scholar 

  28. Macy E, Hayes T, Tracy R . Variability in the measurement of C-reactive protein in healthy subjects: implications for reference intervals and epidemiological applications. Clin Chem 1997; 43: 52–58.

    CAS  PubMed  Google Scholar 

  29. Kabbani SS, Watkins MW, Ashikaga T, Terrien EF, Holoch PA, Sobel BE et al. Platelet reactivity characterized prospectively. A determinant of outcome 90 days after percutaneous coronary intervention. Circulation 2001; 104: 181–186.

    Article  CAS  Google Scholar 

  30. Holmes MB, Sobel BE, Howard DB, Schneider DJ . Differences between activation thresholds for platelet P-selectin and glycoprotein IIb-IIIa expression and their clinical implications. Thrombosis Res 1999; 95: 75–82.

    Article  CAS  Google Scholar 

  31. Trip MD, Cats VM, van Capelle FJ, Vreeken J . Platelet hyperreactivity and prognosis in survival of myocardial infarction. N Engl J Med 1990; 322: 1549–1554.

    Article  CAS  Google Scholar 

  32. Thaulow E, Erikssen J, Sandvik L, Stormorkrn H, Cohn PF . Blood platelet count and function are related to total and cardiovascular death in apparently healthy men. Circulation 1991; 84: 613–617.

    Article  CAS  Google Scholar 

  33. Froelicher Jr VF, Brammell H, Davis G, Noquera I, Stewart A, Lancaster MC . A comparison of the reproducibility and physiologic response to three maximal treadmill exercise protocols. Chest 1974; 65: 512–517.

    Article  Google Scholar 

  34. Welk GJ, Slater CH, Green LW, Jones J, Thompson RW . A comparative evaluation of three accelerometry-based physical activity monitors. Med Sci Sports Exerc 2000; 32: S489–S497 pp.

    Article  CAS  Google Scholar 

  35. Yesavage JA, Brink TL, Rose TL . Development and validation of a geriatric depression screening scale—a preliminary report. J Psychiatr Res 1983; 17: 37–49.

    Article  CAS  Google Scholar 

  36. Smith SC, Allen J, Blair SN, Bonow RO, Brass LM, Fonarow GC et al. AHA/ACC; National Heart, Lung, and Blood Institute. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. Circulation 2006; 113: 2363–2372.

    Article  Google Scholar 

  37. Rosita GA, D'Agostino RB, Massaro J, Lipinska I, Mittleman MA, Sutherland P et al. Association between obesity and a prothrombotic state: the Framingham Offspring Study. Thromb Haemost 2004; 91: 683–689.

    Article  Google Scholar 

  38. Rossouw JE, Lewis B, Rifkind BM . The value of lowering cholesterol after myocardial infarction. N Engl J Med 1990; 323: 1112–1119.

    Article  CAS  Google Scholar 

  39. Malmberg K, Båvenholm P, Hamsten A . Clinical and biochemical factors associated with prognosis after myocardial infarction at a young age. J Am Coll Cardiol 1994; 24: 592–599.

    Article  CAS  Google Scholar 

  40. Nissen SE, Wolski K . Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007; 356: 2457–2471.

    Article  CAS  Google Scholar 

  41. Ross R, Dagnone D, Jones PJ, Smith H, Paddags A, Hudson R et al. Reduction in obesity and related comorbid conditions after diet-induced weight loss or exercise-induced weight loss in men. A randomized, controlled trial. Ann Intern Med 2000; 133: 92–103.

    Article  CAS  Google Scholar 

  42. Fontana L, Villareal DT, Weiss EP, Racette SB, Steger-May K, Klein S et al. Caloric restriction or exercise: Effects of coronary heart disease risk factors. A randomized controlled trial. Am J Physiol Endocrinol Metab 2007; 293: E197–E202.

    Article  CAS  Google Scholar 

  43. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106: 3143–3421.

    Article  Google Scholar 

  44. Conus F, Rabasa-Lhoret R, Péronnet F . Characteristics of metabolically obese normal-weight (MONW) subjects. Appl Physiol Nutr Metab 2007; 32: 4–12.

    Article  Google Scholar 

  45. Ogden CL, Carroll MD, Curtin LR, McDowell MA, Tabak CJ, Flegal KM . Prevalence of overweight and obesity in the United States, 1999–2004. JAMA 2006; 295: 1549–1555.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

This work was supported by NIH Grant RO1-HL72851 (P Ades PI) and the General Clinical Research Center, University of Vermont (UVM) College of Medicine (RR-109).

Author information

Authors and Affiliations

  1. Division of Cardiology, University of Vermont College of Medicine, Burlington, VT, USA

    P A Ades, P D Savage, M J Toth, D J Schneider, M C Audelin, J Y Bunn & M Ludlow

Authors
  1. P A Ades
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. P D Savage
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M J Toth
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. D J Schneider
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. M C Audelin
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. J Y Bunn
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. M Ludlow
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to P A Ades.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ades, P., Savage, P., Toth, M. et al. The influence of obesity and consequent insulin resistance on coronary risk factors in medically treated patients with coronary disease. Int J Obes 32, 967–974 (2008). https://doi.org/10.1038/ijo.2008.6

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ijo.2008.6

Keywords

This article is cited by

Search

Advanced search

Quick links